Global Idiopathic Pulmonary Fibrosis Market value was US$ 2,073.9 million in 2021 and is estimated to reach US$ 4,298.8 million by 2030, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period from 2022 to 2030.
The global idiopathic pulmonary fibrosis (IPF) market is experiencing substantial growth in terms of revenue. This grave and persistent condition affects the delicate tissue surrounding the air sacs, known as alveoli, within the lungs. The surge in IPF cases, coupled with the expanding elderly population and the rising number of smokers, acts as a catalyst for the market’s revenue growth. Furthermore, the market is set to benefit from the escalating research and development investments made by key industry players, which will undoubtedly enhance the market’s revenue share.
A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/idiopathic-pulmonary-fibrosis-market
Idiopathic pulmonary fibrosis (IPF) stands as the most prevalent among idiopathic interstitial pneumonia. Research conducted by the National Organization for Rare Disorders (NORD) reveals that in the general population, estimates have varied from 2 to 29 individuals per 100,000 being affected by this condition. Studies indicate that the incidence of idiopathic pulmonary fibrosis in younger individuals is approximately 5 to 6 cases per 100,000 people annually, while in individuals over the age of 60, this number increases to 11 cases per 100,000 persons.
It is worth noting that around 5 to 10% of idiopathic pulmonary fibrosis cases can be due to a genetic predisposition. Typically, the impact of idiopathic pulmonary fibrosis is more prevalent among individuals in their fifties and sixties, with a higher likelihood of males being affected compared to females. Consequently, the growing prevalence of IPF serves as a driving force for market growth.
Additionally, the expanding elderly population contributes to the growth of the market. The United Nations’ World Population Prospects, after revision, indicate that the elderly population (65 years and older) has reached 16%, accounting for one in six individuals worldwide as of 2021. Furthermore, studies have shown that the incidence of IPF among younger individuals is around 6 cases per 100,000, whereas in the older population, this number increases to 11 cases per 100,000. Considering that IPF is more prevalent among individuals above the age of 50, these statistics highlight the significance of the aging population in driving the market’s growth.
Igniting Opportunities: The Rising Smoker Population and its Enormous Impact on the Market
The impact of smoking on the incidence of IPF cannot be overlooked. Studies estimate that more than 16 million Americans suffer from smoking-related diseases, underlining the widespread health implications. This alarming statistic highlights the global rise in the smoker population, which is expected to have a significant impact on the market’s size.
The prevalence of tobacco use among IPF patients ranges from 41% to 83%, with current or former smokers consistently overrepresented in this population. Moreover, smoking has been identified as a potential risk factor for the development of IPF. Our survey indicates that smoking may have detrimental effects on the survival of IPF patients. Given that IPF is predominantly considered a disease of aging, there is speculation that smoking may contribute to the development.
Recent Advancement in Medicine: Leveraging Potential for Market Players
The investment in research holds the key to addressing these limitations and revolutionizing patient care on a global scale. By allocating funds to the Pulmonary Fibrosis Foundation (PFF) research, we pave the way for groundbreaking therapies that will significantly enhance the lives of individuals affected by pulmonary fibrosis (PF).
The current landscape of the Idiopathic Pulmonary Fibrosis (IPF) market is marked by a lack of sufficient options, with only two licensed pharmaceutical treatments available worldwide: Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s (BI) Ofev (nintedanib), both of which received FDA approval in 2014. However, in a momentous development in August 2023, Lupin, an innovative multinational pharmaceutical company, received FDA approval for its generic pirfenidone tablets in both 267mg and 801mg presentations.
In addition to the aforementioned developments, the pharmaceutical company Humanetics is leveraging a federal grant to finance a comprehensive series of studies. These studies have a singular objective: to accelerate the development of BIO 300 as a potential treatment for idiopathic pulmonary fibrosis (IPF). One of the key areas of focus is evaluating the efficacy of this treatment candidate in alleviating lung scarring, also known as fibrosis.
Perfieniodone Accounted for the Highest Revenue Share
Pirfenidone, an orally administered medication, offers a multifaceted approach to combating idiopathic pulmonary fibrosis (IPF). With its antifibrotic, anti-inflammatory, and antioxidant properties, this drug plays a crucial role in slowing down the progression of the disease.
One of the standout features of pirfenidone is its oral form, which provides patients with a convenient and hassle-free method of administration. This characteristic sets it apart from other therapies available for IPF. By eliminating the need for invasive procedures or frequent hospital visits, pirfenidone enhances the overall experience for patients and facilitates adherence to treatment regimens.
According to a study article released by the NIH in 2021, it has been found that pirfenidone offers survival advantages for individuals diagnosed with idiopathic pulmonary fibrosis (IPF). Consequently, the increasing focus on research and development activities is expected to stimulate the growth of this particular segment.
Furthermore, a recent article published in the Journal of Thoracic Disease in March 2023 highlights that a trial has been registered at the UMIN Clinical Trials Registry. This trial aims to investigate the effectiveness of perioperative pirfenidone therapy in patients with non-small cell lung cancer who also have idiopathic pulmonary fibrosis, with the goal of confirming its preventive effect against postoperative acute exacerbation.
United States Generated US$ 1,171.8 Million in Revenue in the Market
In 2020, the United States emerged as the leading market in terms of size, with a market value of US$ 1,171.8 Million, experiencing the highest Compound Annual Growth Rate (CAGR) of 9.9%. The global prevalence of idiopathic pulmonary fibrosis is estimated to range from 13 to 20 cases per 100,000 individuals. Within the United States, approximately 100,000 individuals are affected by this condition, with 30,000 to 40,000 new cases being identified each year. While familial pulmonary fibrosis is more common, the random form of this condition is less frequently observed.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/idiopathic-pulmonary-fibrosis-market
Smoking is recognized as one of the primary causes of idiopathic pulmonary fibrosis. According to data from the Centers for Disease Control and Prevention (CDC) from 2019, approximately 14% of adults aged 18 and above in the United States (equivalent to over 14 out of every 100 individuals) were cigarette smokers. This indicates that around 34.1 million adults in the United States smoke cigarettes. Additionally, more than 16 million Americans suffer from smoking-related ailments. As a result, the growing number of smokers is expected to drive the growth of the idiopathic pulmonary fibrosis market during the forecast period.
List of Prominent Players in the Global Idiopathic Pulmonary Fibrosis Market
- Genentech, Inc.
- Boehringer Ingelheim Pharma GmbH, and Co. Kg
- FibroGen, Inc.
- Kadmon Corporation, LLC
- ProMetic LifeSciences
- Biogen, Inc.
- Merck and Co.
- Other Prominent Players
- Esbriet (Pirfenidone)
- Ofev (Nintedanib)
- PRM 151
- The U.S.
- The UK
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/idiopathic-pulmonary-fibrosis-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/